Biogen wins Euro MS approval, but loses patents
نویسندگان
چکیده
منابع مشابه
"Nobody wins, but nobody loses either" - understanding different institutional logics in IT public-private partnerships
Information and communication technologies (ICT) are becoming increasingly important for the provision of public services. Therefore, public-private partnerships (PPP) have become a valuable alternative for implementing, maintaining, and modernizing public ICT infrastructures. However, information technology (IT) partnerships between public and private parties are difficult endeavours due to di...
متن کاملThe Economic Crisis, Employees, and Executives: Who Wins? Who Loses?
This article explores the effects of the current economic crisis from the perspective of who wins and who loses among employees and executives. While both executives and employees have suffered financially from this recession, employee losses are disproportionately more profound and are likely to have more lasting impact than losses experienced by executives. In a number of instances, executive...
متن کاملWho wins and who loses? Public transfer accounts for US generations born 1850 to 2090.
Public transfer programs in industrial nations are thought to benefit the elderly through pension and health care programs at the expense of the young and future generations. However, this intergenerational picture changes if public education is also considered as a transfer program. We calculate the net present value (NPV) of benefits received minus taxes paid for US generations born 1850 to 2...
متن کاملSlow but steady wins the drug race
Without the SNF-6 acetylcholine transporter (bottom) mutant muscles fall apart. K im /M ac m ill an they are mutant for various members of the dystrophinglycoprotein complex (DGC), which links intracellular actin to extracellular laminin. But now, Hongkyun Kim, Steven McIntire (University of California, San Francisco, CA), and colleagues suggest that loss of the DGC results in loss of an associ...
متن کاملBRCA1 loses the ring but lords over resistance.
Germline breast cancer 1 (BRCA1) variants are associated with a high risk of breast and ovarian cancers. Many BRCA1-mediated cancers are initially responsive to platinum-based therapy; however, resistance commonly develops. The BRCA1185delAG mutation is common in the Ashkenazi Jewish population and has been thought to result in loss of function due to the introduction of a stop codon in the 5' ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 1997
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0597-410